Welcome to our dedicated page for Voyager Therapeutics news (Ticker: VYGR), a resource for investors and traders seeking the latest updates and insights on Voyager Therapeutics stock.
Voyager Therapeutics, Inc. develops genetic medicines and other neurotherapeutics for neurological diseases, with company updates focused on its CNS pipeline and delivery platforms. Recurring news covers the TRACER AAV capsid discovery platform, intravenous gene-therapy research, Voyager NeuroShuttle nonviral delivery work, and programs addressing Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, ALS, frontotemporal dementia and other central nervous system disorders.
Company announcements also cover tau-focused assets such as VY1706 and VY7523, small-molecule discovery collaboration targeting TDP-43 pathology, scientific conference presentations, and periodic financial and operating results. Voyager’s updates frequently connect pipeline spending, collaboration revenue, partner programs and balance-sheet resources with its genetic-medicine development strategy.
Voyager Therapeutics (Nasdaq: VYGR) announced that CEO Alfred W. Sandrock, Jr., M.D., Ph.D., will participate in a pre-recorded fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference.
The on-demand webcast will be available via the Investors section of Voyager’s website starting 7:00 a.m. ET on June 15, 2026, and will be archived for at least 30 days.
Voyager Therapeutics (Nasdaq: VYGR) received FDA IND clearance for VY1706, an IV-delivered gene therapy designed to reduce intracellular and extracellular tau in the brain for early Alzheimer’s disease.
The multi-site, open-label, dose-escalation trial will enroll up to 18 adults, with dosing expected in H2 2026.
Voyager Therapeutics (Nasdaq: VYGR) reported 3-month GLP toxicology data for VY1706, an investigational tau-silencing gene therapy for Alzheimer’s disease. A single IV dose was well tolerated in non-human primates up to 5E13 vg/kg and lowered tau protein up to 64% in key brain regions.
The IND process for VY1706 is on track for Q2 2026, supporting expected first-in-human dosing in H2 2026. Additional ASGCT presentations highlighted TRACER-powered AAV capsids with up to 100X higher muscle expression than AAV9 in mice, antibody-evasive “stealth” capsids, and manufacturing optimizations.
Voyager Therapeutics (Nasdaq: VYGR) reported Q1 2026 results and program milestones. Key items: completed IND‑enabling GLP toxicology for VY1706 and NBIB‑'223, expects FDA IND actions and first‑in‑human dosing of VY1706 in H2 2026, anticipates tau PET imaging data for VY7523 in H2 2026, and ended Q1 with $171.7M cash providing runway into 2028.
Q1 financials: collaboration revenue $2.6M, R&D $24.6M, G&A $8.3M, net loss $27.9M. Neurocrine intends to seek a clinical start for NBIB‑'223 in H2 2026 pending IND clearance.
Voyager Therapeutics (Nasdaq: VYGR) announced eight oral and poster presentations at ASGCT 2026 (May 11–15, Boston), highlighted by a late-breaking oral presentation of 3-month GLP non-human primate toxicology data for IV-delivered tau-silencing gene therapy VY1706 for Alzheimer’s disease.
Voyager anticipates submitting an IND in Q2 2026 to support projected first-in-human dosing in H2 2026. Additional presentations cover TRACER capsid innovations, muscular/neuromuscular targeting, immune evasion, and manufacturability advances.
Voyager (Nasdaq: VYGR) reported Q4 and full-year 2025 results and outlined 2026 milestones. Key clinical catalysts include expected first-in-human dosing of VY1706 and tau PET data for VY7523 in H2 2026. Cash, cash equivalents and marketable securities were $201.7M, with runway expected into 2028.
Collaboration revenue was $15.3M in Q4 2025 and $40.4M for the year; net loss was $119.7M for 2025. Partnerships with Neurocrine and Novartis advanced, including a $3M milestone from Neurocrine in Q4 2025.
Voyager Therapeutics (Nasdaq: VYGR) will present at multiple investor conferences in Feb–Mar 2026, including Guggenheim, Oppenheimer, TD Cowen, Leerink, and Stifel events.
Scheduled fireside chat times and locations are listed, and a webcast of the Oppenheimer session will be available via the company’s Investors website with a replay archived for at least 30 days.
Voyager Therapeutics (Nasdaq: VYGR) and Transition Bio announced a drug discovery collaboration and license option agreement on November 10, 2025 to discover selective small molecules targeting TDP-43 for ALS and frontotemporal dementia (FTD).
Under the deal, Transition Bio will discover and optimize small molecules through nomination of a development candidate, at which point Voyager has an option to license worldwide rights. Transition Bio received a single-digit million-dollar upfront payment and may earn research, development, commercial and net-sales milestone payments totaling up to $500 million, plus royalties in the high single-digit to low double-digit range. TDP-43 pathology is cited as present in over 90% of ALS cases and up to 45% of FTD cases.
Voyager Therapeutics (Nasdaq: VYGR) reported third quarter 2025 results and program updates on Nov 10, 2025, highlighting tau-focused clinical progress, a new NeuroShuttle discovery program, and a small-molecule collaboration for TDP-43 disorders.
Key facts: cash $229M (9/30/25) with runway into 2028; collaboration revenue $13.4M vs $24.6M year‑ago; R&D $35.9M; net loss $27.9M. VY7523 MAD dosing ongoing; VY1706 IND‑enabling work with clinical start anticipated in 2026. Neurocrine partnership triggered a $3M milestone payable to Voyager in Q4 2025. Transition Bio collaboration gives Voyager an option to license candidates with up to $500M in potential milestones.
Voyager Therapeutics (NASDAQ:VYGR), a biotechnology company focused on neurological diseases, has announced its participation in six major investor conferences in September 2025. The company will present at the Citi Biopharma, Wells Fargo Healthcare, Cantor Global Healthcare, Morgan Stanley Global Healthcare, Baird Global Healthcare, and H.C. Wainwright Global Investment conferences.
During these presentations, Voyager plans to discuss its non-viral delivery platform and novel receptor-binding molecules for transporting neurotherapeutics across the blood-brain barrier. Webcasts for the Citi and Baird presentations will be available on the company's investor relations website for at least 30 days.